MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/mdc3.14191

Медицинская библиотека · Movement disorders clinical practice · 2024

Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.

Vijiaratnam Nirosen, Girges Christine, Athauda Dilan, King Alexa, Auld Grace, McComish Rachel, Chowdhury Kashfia, Skene Simon, Maclagan Kate, Chaudhuri Kallol Ray, Libri Vincenzo, Dickson John, Foltynie Thomas

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The dopamine transporter striatal binding ratio (DAT SBR) has been used as an outcome measure in Parkinson's disease (PD) trials of potential disease-modifying therapies; however, both patient characteristics and analysis approach potentially complicate its interpretation.

OBJECTIVE

The aim was to explore how well DAT SBR reflects PD motor severity across different striatal subregions and the relationship to disease duration, and side of onset.

METHODS

DAT SBR for the anterior and posterior putamen and caudate in both hemispheres was obtained using validated automated quantitative software on baseline scans of 132 patients recruited for the Exenatide PD2 and PD3 trials. Associations between mean and lateralized SBR subregions (posterior and anterior putamen and caudate) and summed and lateralized motor characteristics were explored using regression analysis. Analyses were repeated considering disease duration and limiting analysis to the less-affected hemisphere.

RESULTS

Lateralized bradykinesia was most consistently associated with the loss of DAT uptake in the contralateral anterior putamen. There was much higher variance in the posterior putamen, and in all regions in those with longer duration disease, although bradykinesia remained robustly associated with anterior putaminal DAT uptake even in longer-duration patients. Restricting analyses to the less-affected side did not usefully reduce the variance compared to the overall cohort.

CONCLUSION

These data suggest that DAT SBR could be a useful biomarker in disease-modifying trials, but a focus on anterior striatal subregions and incorporating disease duration into analyses may improve its utility.

Для цитирования: Vijiaratnam Nirosen, Girges Christine, Athauda Dilan, King Alexa, Auld Grace, McComish Rachel, Chowdhury Kashfia, Skene Simon, Maclagan Kate, Chaudhuri Kallol Ray, Libri Vincenzo, Dickson John, Foltynie Thomas. Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.. Movement disorders clinical practice. 2024. DOI: 10.1002/mdc3.14191.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.